This R&D-focused firm is using an aggressive alliance strategy to become a player in drug-eluting stents. by Stephen Levin With the onset of the drug-eluting stent (DES) era in interventional cardiolo
The advent of drug-eluting stents has increased the partnering visibility for companies with biocoatings. Ten years ago, SurModics Inc. , one of the few sizeable "pure play" companies in the biocoa
Acquisitions Xenova sells assets to Bioventix Bioventix Ltd. (Cambridge, UK) Xenova Group PLC (Slough, Berkshire, UK) For £800k ($1.5mm) in cash, oncology and addiction therapeutics company Xenova G